

Conrado M Fernández-Rodríguez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3312617/publications.pdf>

Version: 2024-02-01

22
papers

625
citations

759233

12
h-index

713466

21
g-index

25
all docs

25
docs citations

25
times ranked

1247
citing authors

#	ARTICLE	IF	CITATIONS
1	Plan asistencial coordinado para la eliminación del virus de la hepatitis C en el centro de ayuda integral al drogodependiente (CAID). <i>Gastroenterología Y Hepatología</i> , 2021, 44, 214-220.	0.5	0
2	Hepatocellular carcinoma risk in hepatitis C stage 3 fibrosis after sustained virological response with direct acting antivirals. <i>Liver International</i> , 2021, 41, 2885-2891.	3.9	9
3	Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 519-530.	3.7	17
4	A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus Advanced Fibrosis. <i>Hepatology</i> , 2020, 72, 1924-1934.	7.3	56
5	One-step diagnosis. A key tool for the elimination of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 513-514.	0.3	1
6	Digestive units in the National Health System of the 21st century. Organizational and management standards for a patient-centered service. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 144-149.	0.3	2
7	Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-8.	1.4	3
8	Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 264-269.	0.3	16
9	The contribution of telemedicine to hepatitis C elimination in a correctional facility. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 550-555.	0.3	24
10	Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 129-133.	0.3	3
11	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017, 66, 485-493.	3.7	225
12	Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?. <i>BMC Gastroenterology</i> , 2017, 17, 168.	2.0	31
13	RECALAD. Patient care at National Health System Digestive Care Units - A pilot study, 2015. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 110, 44-50.	0.3	3
14	Disruptive therapeutic innovation and the opportunity to eliminate a chronic disease - The issue of chronic hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 807-808.	0.3	2
15	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. <i>Gastroenterología Y Hepatología</i> , 2014, 37, 1-8.	0.5	2
16	Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 175.	1.1	25
17	Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes. <i>World Journal of Gastroenterology</i> , 2011, 17, 1558.	3.3	16
18	Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response. <i>American Journal of Gastroenterology</i> , 2010, 105, 2164-2172.	0.4	62

#	ARTICLE	IF	CITATIONS
19	Reply:. Hepatology, 2009, 50, 2055-2055.	7.3	0
20	Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver International, 2004, 24, 477-483.	3.9	73
21	Factors Influencing the Rate of Fibrosis Progression in Chronic Hepatitis C. Digestive Diseases and Sciences, 2004, 49, 1971-1976.	2.3	33
22	Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Digestive Diseases and Sciences, 2001, 46, 1313-1320.	2.3	18